KRAS and neoplasm: Among cases with respective tumor marker data, 19.8% were MSI-H (n = 719), 24.3% were CIMP-positive (n = 841), 18.4% were BRAF-mutated (n = 654), and 32.0% were KRAS-mutated (n = 1098).